With a strong background in the engineered T cell therapy industry, Dr. Jingwei Lu has proven to be a leading innovator in both R&D and business development. Prior to founding Synlico, Dr. Lu played a pivotal role in the R&D division at Eureka Therapeutics, where he led the development of de-novel designed engineered T cell platform ARTEMISTM. He is the first inventor of six key US patents on the platform, four of which are already granted. Multiple pipelines generated from the platform are currently in clinical trials. Dr. Lu’s impressive portfolio includes over 50 patents worldwide, including granted and pending, in engineered T cell therapy. Beyond his research expertise, Dr. Lu also has extensive experience in technology and market analysis, and corporate external cooperation at Eureka’s Strategic Alliances Department. Dr. Lu has been an active member of the American Association for Cancer Research (AACR) since 2014.